WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced significant progress in the first quarter of 2025, reporting $3.4 million in revenue from YCANTH. This figure reflects a 16.7% increase from Q4 2024, driven by the dispensing of more than 10,000 applicator units, a milestone for the company.
“I am pleased to report that our focused commercialization strategy is helping to drive increased demand for YCANTH and the demand has allowed us to normalize distributor inventory levels. For the first time, we dispensed more than 10,000 applicator units in a quarter. We are excited by the strong pull-through from our distributors, which translated to $3.4 million in revenue in the first quarter, and we expect this closer alignment between dispensed applicator units and revenue to continue going forward,” said Dr. Jayson Rieger, President and CEO of Verrica Pharmaceuticals.
Verrica also shared updates on its advancing clinical pipeline, highlighting continued momentum for its novel treatments. The company is working with development partner Torii Pharmaceutical to initiate a global Phase 3 program for YCANTH in treating common warts. Additionally, Verrica recently completed an end-of-Phase 2 meeting with the FDA for VP-315, its oncolytic peptide candidate targeting basal cell carcinoma.
“Furthermore, we saw momentum in dispensed applicator units build throughout the first quarter and we are looking to build on that momentum in the second quarter,” Dr. Rieger added. “In parallel with our commercial progress, Verrica’s clinical-stage pipeline also continues to advance. Meanwhile, we continue to advance our novel oncolytic peptide, VP-315, which has shown promising safety and efficacy data in a Phase 2 trial for the treatment of basal cell carcinoma, as we have recently held our end-of-Phase 2 meeting with the FDA that will help us to design a Phase 3 program.”
With record-breaking demand for YCANTH and advancements in its diversified pipeline, Verrica Pharmaceuticals demonstrates robust growth and innovation. The company’s strategic commercialization efforts and ongoing clinical trials position it as a key player in delivering novel therapies to address unmet medical needs in dermatology and oncology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.